Overexpression of c-met as a Prognostic Indicator for Transitional Cell Carcinoma of the Urinary Bladder: A Comparison With p53 Nuclear Accumulation PURPOSE: Testicular germ cell tumors (TGCTs) of ...
This article and associated images are based on a poster originally authored by Sarona Jacob Anderson and presented at ELRIG Drug Discovery 2025 in affiliation with University of Salford. This poster ...
Mdm2 and Mdm4 are homologous RING domain-containing proteins that negatively regulate the tumor suppressor p53 under physiological and stress conditions. The RING domain of Mdm2 encodes an ...
Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality. Targeting oncogenes and their interactive partners is an effective ...
Shares have fallen by nearly 40% since 2021 IPO. Oral MDM2 inhibitor milademetan potentially has an efficient path to market via pivotal study in WD/DD LPS (rare cancer). Basket studies in ...
The p53–Mdm2 system is key to tumor suppression. We have recently reported that p53 as well as Mdm2 are capable of supporting DNA replication fork progression. On the other hand, we found that Mdm2 is ...
“Our findings have implications for the natural history of prolonged or repeated SARS-CoV-2 infection as well as design of anti-COVID-19 vaccines that are administered repeatedly as booster shots.” ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Use of alrizomadlin with pembrolizumab appeared to ...
St. Jude Children's Research Hospital scientists have identified a promising combination approach to treat a rare but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback